Conference
Earn CE
Free Samples
Magazine
Subscribe
Videos
Solutions Lab
Macro/Op-Ed
Practice
Science & Tech
Money
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Dental Market Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Sarepta Therapeutics, Inc.
Sarepta Therapeutics Announces Second Quarter 2024 Financial Results and Recent Corporate Developments
August 07, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 31, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics to Announce Second Quarter 2024 Financial Results
July 29, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 28, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics Announces Expanded US FDA Approval of ELEVIDYS to Duchenne Muscular Dystrophy Patients Ages 4 and Above
June 20, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 31, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Gene Therapy Pioneer Jerry R. Mendell, M.D., Named to Inaugural TIME100 Health List of the 100 Most Influential People in Global Health
May 03, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics Announces First Quarter 2024 Financial Results and Recent Corporate Developments
May 01, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 30, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics to Announce First Quarter 2024 Financial Results
April 24, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 29, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics to Present at Upcoming Investor Conferences
March 04, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 29, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics Announces Call for Applications for the 7th Annual Route 79, The Duchenne Scholarship Program
February 29, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Recent Corporate Developments
February 28, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results
February 21, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics Announces U.S. FDA Acceptance of an Efficacy Supplement to Expand the ELEVIDYS Indication
February 16, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 31, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics Announces Positive Data from Part B of MOMENTUM, a Phase 2 Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51
January 29, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics Initiates Screening in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4
January 16, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2023 Net Product Revenue
January 08, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 29, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics Submits Efficacy Supplement to Expand the ELEVIDYS Label to include Duchenne Muscular Dystrophy Patients without Restriction to Age or Ambulatory Status
December 22, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 30, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics to Present at the UBS Biopharma Conference
November 02, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics Announces Third Quarter 2023 Financial Results and Recent Corporate Developments
November 01, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 31, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics Announces Topline Results from EMBARK, a Global Pivotal Study of ELEVIDYS Gene Therapy for Duchenne Muscular Dystrophy
October 30, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Sarepta Therapeutics to Announce Third Quarter 2023 Financial Results
October 25, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Tickers
SRPT
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.